This trial is testing whether adding SDX-7320 to standard chemotherapy eribulin helps people with TNBC and metabolic dysfunction, and whether it is safe.
1 Primary · 2 Secondary · Reporting Duration: 2 years
Experimental Treatment
Non-Treatment Group
55 Total Participants · 3 Treatment Groups
Primary Treatment: SDX-7320 plus Eribulin (safety run-in period) · Has Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: